Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 19/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 18/20 | 0.47 |
| ▸ | GYS1 | P13807 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15906091 | 1.00 | HCRTR2 (0.47) | HCRTR2HCRTR1GYS1 | |
| SCHEMBL15906089 | 1.00 | HCRTR2 (0.47) | HCRTR2HCRTR1GYS1 | |
| SCHEMBL15906125 | 0.90 | HCRTR2 (0.47) | HCRTR2HCRTR1 | |
| SCHEMBL15906123 | 0.90 | HCRTR2 (0.47) | HCRTR2HCRTR1 | |
| SCHEMBL15906115 | 0.90 | HCRTR2 (0.47) | HCRTR2HCRTR1 | |
| SCHEMBL8058230 | 0.87 | HCRTR2 (0.45) | HCRTR2HCRTR1GYS1 | |
| SCHEMBL8071983 | 0.87 | HCRTR2 (0.45) | HCRTR2HCRTR1GYS1 | |
| SCHEMBL13578445 | 0.87 | HCRTR2 (0.45) | HCRTR2HCRTR1GYS1 | |
| SCHEMBL13578446 | 0.87 | HCRTR2 (0.45) | HCRTR2HCRTR1GYS1 | |
| SCHEMBL13578438 | 0.87 | HCRTR2 (0.45) | HCRTR2HCRTR1GYS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2014-10-09 | — | — | US | disclosed |
| US-8791267-B2 | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | HCRTR2 2341/4885HCRTR1 2509/4885GYS1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.